Please try another search
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Robert M. Hershberg | 62 | 2020 | President, CEO & Chairman of the Board |
Jeryl Lynn Hilleman | 67 | 2021 | Independent Director |
Patrick James Heron | 54 | 2020 | Independent Director |
Shelley Chu | 53 | 2021 | Independent Director |
Julie Louise Gerberding | 69 | 2021 | Independent Director |
Jaime Sepulveda | 69 | 2021 | Independent Director |
Gary Dubin | 67 | 2022 | Director |
Nanette Cocero | 60 | 2023 | Independent Director |
Aditya Kohli | 36 | 2021 | Chief Business Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review